Abbott has announced it has reached an agreement with DexCom, Inc. to settle all outstanding patent disputes between the ...

Abbott is one of the biggest healthcare companies in the world. With over 400 consecutive quarterly dividend payouts and 53 ...

In a report released on December 20, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report), ...

Abbott Laboratories is rated a Buy due to growth indicators, diversified portfolio, strong profit margin. Read an investment ...

In a report released today, Adam Maeder from Piper Sandler maintained a Buy rating on Abbott Laboratories (ABT – Research Report), with a price ...

M&T Bank Corp lessened its holdings in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 6.3% during the 3rd quarter, ...

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and ...

Investors feel optimistic about Abbott's robust strength in the EPD and Nutrition businesses. Yet, unfavorable forex impacts are concerning.

New Delhi: Abbott Healthcare has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to manufacture and market Ursodeoxycholic ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.